JP2008521928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521928A5
JP2008521928A5 JP2007544545A JP2007544545A JP2008521928A5 JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5 JP 2007544545 A JP2007544545 A JP 2007544545A JP 2007544545 A JP2007544545 A JP 2007544545A JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5
Authority
JP
Japan
Prior art keywords
cancer
medicament
group
medicament according
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007544545A
Other languages
English (en)
Japanese (ja)
Other versions
JP5676071B2 (ja
JP2008521928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043668 external-priority patent/WO2006060676A1/en
Publication of JP2008521928A publication Critical patent/JP2008521928A/ja
Publication of JP2008521928A5 publication Critical patent/JP2008521928A5/ja
Application granted granted Critical
Publication of JP5676071B2 publication Critical patent/JP5676071B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007544545A 2004-12-03 2005-12-02 腫瘍性疾患を治療するための組成物及び方法 Expired - Lifetime JP5676071B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63316104P 2004-12-03 2004-12-03
US60/633,161 2004-12-03
PCT/US2005/043668 WO2006060676A1 (en) 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012198263A Division JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Division JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2008521928A JP2008521928A (ja) 2008-06-26
JP2008521928A5 true JP2008521928A5 (enExample) 2009-01-22
JP5676071B2 JP5676071B2 (ja) 2015-02-25

Family

ID=36118298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007544545A Expired - Lifetime JP5676071B2 (ja) 2004-12-03 2005-12-02 腫瘍性疾患を治療するための組成物及び方法
JP2012198263A Expired - Lifetime JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Expired - Fee Related JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012198263A Expired - Lifetime JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Expired - Fee Related JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Country Status (17)

Country Link
US (5) US20070225350A1 (enExample)
EP (1) EP1830838B1 (enExample)
JP (3) JP5676071B2 (enExample)
KR (1) KR101282191B1 (enExample)
CN (2) CN101155582B (enExample)
AU (1) AU2005311709B2 (enExample)
BR (1) BRPI0517135B1 (enExample)
CA (1) CA2588923C (enExample)
DK (1) DK1830838T3 (enExample)
ES (1) ES2396762T3 (enExample)
IL (3) IL183506A (enExample)
MX (1) MX2007006526A (enExample)
NZ (1) NZ555439A (enExample)
PL (1) PL1830838T3 (enExample)
SG (1) SG157365A1 (enExample)
WO (1) WO2006060676A1 (enExample)
ZA (1) ZA200704402B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7144723B2 (en) * 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1638552B1 (en) * 2003-06-20 2011-03-02 Nereus Pharmaceuticals, Inc. Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
BRPI0509824A (pt) * 2004-04-30 2007-10-09 Nereus Pharmaceuticals Inc compostos heterocìclicos [3.2.0] e métodos de uso dos mesmos
PL1830838T3 (pl) * 2004-12-03 2013-07-31 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia chorób neoplastycznych
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US8999289B2 (en) * 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
WO2007056335A2 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CN103739515B (zh) 2006-02-14 2015-11-25 哈佛大学的校长及成员们 组蛋白去乙酰化酶抑制剂
MX2008012847A (es) 2006-04-06 2008-10-13 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y analogos de la misma.
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010009860A (es) 2008-03-07 2010-09-30 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y sus analogos.
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
CA2726537A1 (en) * 2008-06-06 2009-12-10 University Health Network 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US20110207627A1 (en) * 2008-08-13 2011-08-25 George Mason University Ex vivo therapeutics screening of living bone marrow cells for multiple myeloma
US20110319427A1 (en) * 2009-03-05 2011-12-29 University Health Network Use of 5ahq and bortezomib for the treatment of hematological diseases
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US20130173295A1 (en) * 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
CA2890725A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
JP2019524894A (ja) 2016-08-19 2019-09-05 セルジーン インターナショナル ツー エスアーエールエル マリゾミブのモルフィック形態およびその使用
US11141389B2 (en) 2017-01-31 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Agents that inhibit NGLY1 and methods of use thereof
JP7498475B2 (ja) * 2020-01-31 2024-06-12 株式会社セラバイオファーマ 多発性骨髄腫の治療剤
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CZ301771B6 (cs) * 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
EP0979096B1 (en) * 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP1004573B1 (en) * 1997-08-04 2002-10-30 Taisho Pharmaceutical Co., Ltd Aryloxyaniline derivatives
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
WO1999009006A1 (en) 1997-08-15 1999-02-25 Soucy Francois SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
DE69842004D1 (de) * 1997-11-21 2010-12-30 Purdue Neuroscience Co Substituierte 2-aminoacetamide und anwendung davon
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
CN1142909C (zh) * 1998-03-26 2004-03-24 盐野义制药株式会社 具有抗病毒活性的吲哚衍生物
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
NZ511197A (en) 1998-10-20 2003-08-29 Millenium Pharmaceuticals Inc Method for monitoring proteasome inhibitor drug action
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
EP2301565A1 (de) 2000-10-12 2011-03-30 ViroLogik GmbH Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
US7144723B2 (en) 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
DE50313092D1 (de) * 2002-04-05 2010-10-28 Virologik Gmbh Mittel zur behandlung von flaviviridae-infektionen
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
CN1845925B (zh) * 2003-02-14 2010-11-03 赢泰医药科技发展有限公司 取代的杂环化合物
EP1638552B1 (en) * 2003-06-20 2011-03-02 Nereus Pharmaceuticals, Inc. Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
BRPI0509824A (pt) * 2004-04-30 2007-10-09 Nereus Pharmaceuticals Inc compostos heterocìclicos [3.2.0] e métodos de uso dos mesmos
US20060264495A1 (en) * 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7579371B2 (en) * 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1771411A1 (en) 2004-07-12 2007-04-11 Bayer CropScience Aktiengesellschaft Substituted 2-pyrrolidone derivatives as fungicides and insecticides
CA2590334A1 (en) 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2006060819A2 (en) 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
PL1830838T3 (pl) * 2004-12-03 2013-07-31 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia chorób neoplastycznych
WO2006060609A1 (en) 2004-12-03 2006-06-08 Honeywell International Inc. Gas jet control for inertial measurement unit
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US20060287520A1 (en) * 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
EP1931679A4 (en) 2005-08-10 2009-07-29 Harvard College ANALOGUE OF SALINOSPORAMIDE A
US7572606B1 (en) * 2005-09-09 2009-08-11 Nereus Pharmaceuticals, Inc. Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
WO2007056335A2 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
MX2008012847A (es) 2006-04-06 2008-10-13 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y analogos de la misma.
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US8088923B2 (en) * 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010009860A (es) 2008-03-07 2010-09-30 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y sus analogos.
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
US8772724B2 (en) 2011-01-05 2014-07-08 Intel-Ge Care Innovations Llc Low power, inexpensive velocity detection using a PIR array

Similar Documents

Publication Publication Date Title
JP2008521928A5 (enExample)
JP2006514689A5 (ja) １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
JP2006523216A5 (enExample)
JP2013507415A5 (enExample)
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
JP2005525345A5 (enExample)
JP2009514880A5 (enExample)
JP2018535923A (ja) 胆道癌の治療
JP2017517548A5 (enExample)
JP2009541223A5 (enExample)
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
JP2015536986A5 (enExample)
JP2016501221A5 (enExample)
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
JP2015532296A5 (enExample)
JP2015520753A5 (enExample)
JP2008528671A5 (enExample)
JP2018534286A5 (enExample)
RU2008138560A (ru) Улучшенные способы лечения опухолей
JP2020523354A5 (enExample)
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2015517523A5 (enExample)
JP2009506054A5 (enExample)